

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P32498C1	PRED. APPLN. NO. 10/168,872
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Robin Edward Buckingham	
		PRED. FILING DATE 04 October 2002	PRED. GROUP 1614

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
Re	5,965,584	10/1999	Ikeda Hitoshi, et al.			

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
Re	WO 00/27434	05/2000	PCT				
	0 861 666	09/1998	EPO				
	0 930 076	07/1999	EPO				
	0 306 228	03/1989	EPO				
Re	WO 93/08799	05/1999	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Re	CA	Shimoyama, et al., "Hemodynamic Basis for the Acute Cardiac Effects of Troglitazone in Isolated Perfused Rat Hearts", <i>Diabetes</i> , <u>48(3)</u> : 609-615 (1999).
Re	CB	Dagogo-Jack, et al., "Pathophysiology of Type 2 Diabetes and Modes of Action of Therapeutic Inventions", <i>Arch. Int. Med.</i> , <u>157(16)</u> : 1802-1817 (1997).
Re	CC	Hosokawa, et al., "Troglitazone Inhibits Bicarbonate Secretion in Rat and Human Duodenum", <i>J. Pharmacol. Exp. Ther.</i> , <u>290(3)</u> : 1080-1084 (1999).
EXAMINER <i>Re. Weigden</i>		DATE CONSIDERED <i>10-31-04</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		